Table 5 Results of RCTs comparing the... | American Society of Hematology

Table 5

Results of RCTs comparing the efficacy of smaller field radiotherapy plus chemotherapy to larger field radiotherapy

Trial	Intervention control participants	OS, %	FFTF, %	PFS, %	EFS, %	Late AE, %	Response, %	Median follow-up	Reference
EORTC-GELA H7 (favorable)	Arm A: STNI (n = 165)	*92 (95% CI: 85-95) vs 92 (95% CI: 84-95) at 10 y; P = .79	NR	NR	*78 (95% CI: 70-83) vs 88 (95% CI: 82-92) at 10 y; P = .0113	SC at 10 y: 2.3 (95% CI: 0.7-7.4) vs 2.9 (95%CI: 0.9-9.0)	CR: 94 vs 91; P = NS	105 mo	24
EORTC-GELA H7 (favorable)	Arm B: 6 × EPBV + IFRT (n = 168)	*92 (95% CI: 85-95) vs 92 (95% CI: 84-95) at 10 y; P = .79	NR	NR		SC at 10 y: 2.3 (95% CI: 0.7-7.4) vs 2.9 (95%CI: 0.9-9.0)	CR: 94 vs 91; P = NS	105 mo	24
EORTC-GELA H8 (favorable)	Arm A: STNI (n = 272)	*92 (95% CI: 87-95) vs 97 (95% CI: 92-99) at 10 y; P = .001	NR	NR	*68 (95% CI: 64-76) vs 93 (95% CI: 85-97) at 10 y; P < .001	SC at 10 y: 3.4 (95% CI: 1.3-8.4) vs 3.2 (95% CI: 1.2-8.0); P = .75 Death: 7 vs 1	CR/CRu at the end of chemotherapy: NA vs 76	92 mo	25
EORTC-GELA H8 (favorable)	Arm B: combination of 3 × MOPP-ABV + IFRT (n = 270)	*92 (95% CI: 87-95) vs 97 (95% CI: 92-99) at 10 y; P = .001	NR	NR	*68 (95% CI: 64-76) vs 93 (95% CI: 85-97) at 10 y; P < .001		CR/Cru at the end of treatment: 95 vs 93	92 mo	25

Trial	Intervention control participants	OS, %	FFTF, %	PFS, %	EFS, %	Late AE, %	Response, %	Median follow-up	Reference
EORTC-GELA H7 (favorable)	Arm A: STNI (n = 165)	*92 (95% CI: 85-95) vs 92 (95% CI: 84-95) at 10 y; P = .79	NR	NR	*78 (95% CI: 70-83) vs 88 (95% CI: 82-92) at 10 y; P = .0113	SC at 10 y: 2.3 (95% CI: 0.7-7.4) vs 2.9 (95%CI: 0.9-9.0)	CR: 94 vs 91; P = NS	105 mo	24
EORTC-GELA H7 (favorable)	Arm B: 6 × EPBV + IFRT (n = 168)	*92 (95% CI: 85-95) vs 92 (95% CI: 84-95) at 10 y; P = .79	NR	NR		SC at 10 y: 2.3 (95% CI: 0.7-7.4) vs 2.9 (95%CI: 0.9-9.0)	CR: 94 vs 91; P = NS	105 mo	24
EORTC-GELA H8 (favorable)	Arm A: STNI (n = 272)	*92 (95% CI: 87-95) vs 97 (95% CI: 92-99) at 10 y; P = .001	NR	NR	*68 (95% CI: 64-76) vs 93 (95% CI: 85-97) at 10 y; P < .001	SC at 10 y: 3.4 (95% CI: 1.3-8.4) vs 3.2 (95% CI: 1.2-8.0); P = .75 Death: 7 vs 1	CR/CRu at the end of chemotherapy: NA vs 76	92 mo	25
EORTC-GELA H8 (favorable)	Arm B: combination of 3 × MOPP-ABV + IFRT (n = 270)	*92 (95% CI: 87-95) vs 97 (95% CI: 92-99) at 10 y; P = .001	NR	NR	*68 (95% CI: 64-76) vs 93 (95% CI: 85-97) at 10 y; P < .001		CR/Cru at the end of treatment: 95 vs 93	92 mo	25

NA, not available.

Primary outcome.